Foley Partner Lawrence Vernaglia, member of the firm’s Health Care Industry Team, as well as Foley Partner Mike Crossen, member of the firm’s Government Solutions Practice Group, and Mike Capuano, Director of the firm’s Public Affairs Practice Group, will be speaking at the HCCA 2020 Boston Regional Healthcare Compliance Conference.
Lawrence will be part of the “Covid-19 Compliance Panel Discussion” at 11:00 a.m. CT with Jim Bryant (Brigham Health), Beth Gutoff (Elliot Health System), and Rick King (UMass Memorial Medical Center). The panel will share their experiences as it relates to the COVID-19 pandemic with regard to key compliance risks, impacts to compliance programs, and post-pandemic planning.
Mike Capuano and Mike Crossen are co-hosting the “Reading the Tea Leaves: Projecting Change in the Healthcare Industry Relating to the 2020 Presidential Election” panel at 3:30 p.m. CT, and will focus on key health policy issues on the platforms of each candidate, predictions for what changes hospitals and other providers could expect following January 2021 inauguration, and what should a compliance officer be thinking about for project out the next 18 months.
To find out more, or register for the virtual conference, click here.
People
Related Insights
21 October 2024
Events
Legal Overview of the BIOSECURE Act
Foley special counsel John Strom is speaking in the Association for Accessible Medicine’s GRx+Biosims 2024 conference in a panel titled “Legal Overview of the BIOSECURE Act” on October 21.
04 October 2024
Innovative Technology Insights
Decoding California’s Recent Flurry of AI Laws
Governor Newsom signed over 18 AI-related bills into law during September, impacting numerous industries.
17 October 2024
Events
Top Compliance Considerations when Commercializing in the U.S.
Kyle Faget and Nathan "Nate" Beaver, co-chair of Foley's Medical Device and Equipment Area of Focus within the firm's Health Care & Life Sciences Sector, invite you to join us for a webinar on the compliance considerations you need to know when you are commercializing your medical device products in the U.S.